Try a new search

Format these results:

Searched for:

person:kamind02

in-biosketch:true

Total Results:

23


Pulmonary Embolism at CT Pulmonary Angiography in Patients with COVID-19

Kaminetzky, Mark; Moore, William; Fansiwala, Kush; Babb, James S; Kaminetzky, David; Horwitz, Leora I; McGuinness, Georgeann; Knoll, Abraham; Ko, Jane P
Purpose/UNASSIGNED:To evaluate pulmonary embolism (PE) prevalence at CT pulmonary angiography in patients testing positive for coronavirus disease 2019 (COVID-19) and factors associated with PE severity. Materials and Methods/UNASSIGNED:value < .05 was considered significant. Results/UNASSIGNED:< .001). One additional patient with negative results at CT pulmonary angiography had deep venous thrombosis, thus resulting in 38.7% with PE or deep venous thrombosis, despite 40% receiving prophylactic anticoagulation. Other factors did not demonstrate significant PE association. Conclusion/UNASSIGNED:© RSNA, 2020.
PMCID:7336753
PMID: 33778610
ISSN: 2638-6135
CID: 4830512

COVID-19 infections and outcomes in patients with multiple myeloma in New York City: a cohort study from five academic centers

Hultcrantz, Malin; Richter, Joshua; Rosenbaum, Cara; Patel, Dhwani; Smith, Eric; Korde, Neha; Lu, Sydney; Mailankody, Sham; Shah, Urvi; Lesokhin, Alexander; Hassoun, Hani; Tan, Carlyn; Maura, Francesco; Derkach, Andriy; Diamond, Benjamin; Rossi, Adriana; Pearse, Roger N; Madduri, Deppu; Chari, Ajai; Kaminetzky, David; Braunstein, Marc; Gordillo, Christian; Davies, Faith; Jagannath, Sundar; Niesvizky, Ruben; Lentzsch, Suzanne; Morgan, Gareth; Landgren, Ola
IMPORTANCE/OBJECTIVE:New York City is a global epicenter for the SARS-CoV-2 outbreak with a significant number of individuals infected by the virus. Patients with multiple myeloma have a compromised immune system, due to both the disease and anti-myeloma therapies, and may therefore be particularly susceptible to coronavirus disease 2019 (COVID-19); however, there is limited information to guide clinical management. OBJECTIVE:To assess risk factors and outcomes of COVID-19 in patients with multiple myeloma. DESIGN/METHODS:Case-series. SETTING/METHODS:Five large academic centers in New York City. PARTICIPANTS/METHODS:Patients with multiple myeloma and related plasma cell disorders who were diagnosed with COVID-19 between March 10th, 2020 and April 30th, 2020. Exposures: Clinical features and risk factors were analyzed in relation to severity of COVID-19. Main Outcomes and Measures: Descriptive statistics as well as logistic regression were used to estimate disease severity reflected in hospital admissions, intensive care unit (ICU) admission, need for mechanical ventilation, or death. RESULTS:Of 100 multiple myeloma patients (male 58%; median age 68, range 41-91) diagnosed with COVID-19, 74 (74%) were admitted; of these 13 (18%) patients were placed on mechanical ventilation, and 18 patients (24%) expired. None of the studied risk factors were significantly associated (P>0.05) with adverse outcomes (ICU-admission, mechanical ventilation, or death): hypertension (N=56) odds ratio (OR) 2.3 (95% confidence interval [CI] 0.9-5.9); diabetes (N=18) OR 1.1 (95% CI 0.3-3.2); age >65 years (N=63) OR 2.0 (95% CI 0.8-5.3); high dose melphalan with autologous stem cell transplant <12 months (N=7) OR 1.2 (95% CI 0.2-7.4), IgG<650 mg/dL (N=42) OR=1.2 (95% CI 0.4-3.1). In the entire series of 127 patients with plasma cell disorders, hypertension was significantly associated with the combined end-point (OR 3.4, 95% CI 1.5-8.1). CONCLUSIONS AND RELEVANCE/CONCLUSIONS:Although multiple myeloma patients have a compromised immune system due to both the disease and therapy; in this largest disease specific cohort to date of patients with multiple myeloma and COVID-19, compared to the general population, we found risk factors for adverse outcome to be shared and mortality rates to be within the higher range of officially reported mortality rates.
PMCID:7302217
PMID: 32577667
ISSN: n/a
CID: 4493182

Oral Selinexor-Dexamethasone for Triple-Class Refractory Multiple Myeloma

Chari, Ajai; Vogl, Dan T; Gavriatopoulou, Maria; Nooka, Ajay K; Yee, Andrew J; Huff, Carol A; Moreau, Philippe; Dingli, David; Cole, Craig; Lonial, Sagar; Dimopoulos, Meletios; Stewart, A Keith; Richter, Joshua; Vij, Ravi; Tuchman, Sascha; Raab, Marc S; Weisel, Katja C; Delforge, Michel; Cornell, Robert F; Kaminetzky, David; Hoffman, James E; Costa, Luciano J; Parker, Terri L; Levy, Moshe; Schreder, Martin; Meuleman, Nathalie; Frenzel, Laurent; Mohty, Mohamad; Choquet, Sylvain; Schiller, Gary; Comenzo, Raymond L; Engelhardt, Monika; Illmer, Thomas; Vlummens, Philip; Doyen, Chantal; Facon, Thierry; Karlin, Lionel; Perrot, Aurore; Podar, Klaus; Kauffman, Michael G; Shacham, Sharon; Li, Lingling; Tang, Shijie; Picklesimer, Carla; Saint-Martin, Jean-Richard; Crochiere, Marsha; Chang, Hua; Parekh, Samir; Landesman, Yosef; Shah, Jatin; Richardson, Paul G; Jagannath, Sundar
BACKGROUND:Selinexor, a selective inhibitor of nuclear export compound that blocks exportin 1 (XPO1) and forces nuclear accumulation and activation of tumor suppressor proteins, inhibits nuclear factor κB, and reduces oncoprotein messenger RNA translation, is a potential novel treatment for myeloma that is refractory to current therapeutic options. METHODS:We administered oral selinexor (80 mg) plus dexamethasone (20 mg) twice weekly to patients with myeloma who had previous exposure to bortezomib, carfilzomib, lenalidomide, pomalidomide, daratumumab, and an alkylating agent and had disease refractory to at least one proteasome inhibitor, one immunomodulatory agent, and daratumumab (triple-class refractory). The primary end point was overall response, defined as a partial response or better, with response assessed by an independent review committee. Clinical benefit, defined as a minimal response or better, was a secondary end point. RESULTS:A total of 122 patients in the United States and Europe were included in the modified intention-to-treat population (primary analysis), and 123 were included in the safety population. The median age was 65 years, and the median number of previous regimens was 7; a total of 53% of the patients had high-risk cytogenetic abnormalities. A partial response or better was observed in 26% of patients (95% confidence interval, 19 to 35), including two stringent complete responses; 39% of patients had a minimal response or better. The median duration of response was 4.4 months, median progression-free survival was 3.7 months, and median overall survival was 8.6 months. Fatigue, nausea, and decreased appetite were common and were typically grade 1 or 2 (grade 3 events were noted in up to 25% of patients, and no grade 4 events were reported). Thrombocytopenia occurred in 73% of the patients (grade 3 in 25% and grade 4 in 33%). Thrombocytopenia led to bleeding events of grade 3 or higher in 6 patients. CONCLUSIONS:Selinexor-dexamethasone resulted in objective treatment responses in patients with myeloma refractory to currently available therapies. (Funded by Karyopharm Therapeutics; STORM ClinicalTrials.gov number, NCT02336815.).
PMID: 31433920
ISSN: 1533-4406
CID: 4046822

Selective Inhibition of Nuclear Export With Oral Selinexor for Treatment of Relapsed or Refractory Multiple Myeloma

Vogl, Dan T; Dingli, David; Cornell, Robert Frank; Huff, Carol Ann; Jagannath, Sundar; Bhutani, Divaya; Zonder, Jeffrey; Baz, Rachid; Nooka, Ajay; Richter, Joshua; Cole, Craig; Vij, Ravi; Jakubowiak, Andrzej; Abonour, Rafat; Schiller, Gary; Parker, Terri L; Costa, Luciano J; Kaminetzky, David; Hoffman, James E; Yee, Andrew J; Chari, Ajai; Siegel, David; Fonseca, Rafael; Van Wier, Scott; Ahmann, Gregory; Lopez, Ilsel; Kauffman, Michael; Shacham, Sharon; Saint-Martin, Jean-Richard; Picklesimer, Carla D; Choe-Juliak, Cassandra; Stewart, A Keith
Purpose Selinexor, a first-in-class, oral, selective exportin 1 (XPO1) inhibitor, induces apoptosis in cancer cells through nuclear retention of tumor suppressor proteins and the glucocorticoid receptor, along with inhibition of translation of oncoprotein mRNAs. We studied selinexor in combination with low-dose dexamethasone in patients with multiple myeloma refractory to the most active available agents. Patients and Methods This phase II trial evaluated selinexor 80 mg and dexamethasone 20 mg, both orally and twice weekly, in patients with myeloma refractory to bortezomib, carfilzomib, lenalidomide, and pomalidomide (quad-refractory disease), with a subset also refractory to an anti-CD38 antibody (penta-refractory disease). The primary end point was overall response rate (ORR). Results Of 79 patients, 48 had quad-refractory and 31 had penta-refractory myeloma. Patients had received a median of seven prior regimens. The ORR was 21% and was similar for patients with quad-refractory (21%) and penta-refractory (20%) disease. Among patients with high-risk cytogenetics, including t(4;14), t(14;16), and del(17p), the ORR was 35% (six of 17 patients). The median duration of response was 5 months, and 65% of responding patients were alive at 12 months. The most common grade ≥ 3 adverse events were thrombocytopenia (59%), anemia (28%), neutropenia (23%), hyponatremia (22%), leukopenia (15%), and fatigue (15%). Dose interruptions for adverse events occurred in 41 patients (52%), dose reductions occurred in 29 patients (37%), and treatment discontinuation occurred in 14 patients (18%). Conclusion The combination of selinexor and dexamethasone has an ORR of 21% in patients with heavily pretreated, refractory myeloma with limited therapeutic options.
PMID: 29381435
ISSN: 1527-7755
CID: 2933762

Pharmacokinetics-directed Intravenous Busulfan Combined With High-dose Melphalan and Bortezomib as a Conditioning Regimen for Patients With Multiple Myeloma

Barta, Stefan K; Jain, Rishi; Mazumder, Amithaba; Carter, Jason; Almanzar, Lawrence; Browne, Roy; Shahnaz, Samira; Elkind, Richard; Kaminetzky, David; Battini, Ramakrishna; Derman, Olga; Kornblum, Noah; Verma, Amit; Braunschweig, Ira
BACKGROUND:(Mel200) is the most commonly used preparative regimen. Several studies have provided evidence for potential synergism and safety when combining bortezomib (Btz) or busulfan (Bu) with melphalan (Mel). PATIENTS AND METHODS/METHODS:). RESULTS:A total of 19 subjects were enrolled. Their median age was 55 years, and the median follow-up period was 23.7 months. PK testing resulted in 86% of patients achieving an estimated total AUC of 20,000 ± 2500 μM × min. The overall response rate (ORR) at day +100 after ASCT was 100% in the evaluable patients, with 11% of patients achieving a complete response. The 2-year progression-free survival rate was 57.9% (95% confidence interval [CI], 38%-89%), and the 2-year overall survival rate was 88.5% (95% CI, 76%-100%). The most common grade 3 and 4 toxicities were febrile neutropenia, dysphagia/odynophagia, and oral mucositis. No case of hepatic sinusoidal obstruction syndrome developed. One treatment-related mortality occurred before day +100. CONCLUSION/CONCLUSIONS:A preparative regimen of PK-directed IV Bu with Btz and Mel led to an ORR of 100% with acceptable toxicity and should be considered for direct comparison with the Mel200 regimen in future trials.
PMID: 28684379
ISSN: 2152-2669
CID: 3074712

Hodgkin lymphoma patients demonstrate evidence of chronic activation/exhaustion in circulating T cell subsets [Meeting Abstract]

Diefenbach, Catherine S; Raphael, Bruce; Hymes, Kenneth; Grossbard, Michael; Moskovits, Tibor; Kaminetzky, David; Mcshea, Meghan; Martin, Peter; Ruan, Jia; Kozhaya, Lina; Bonakdar, Maryann; Abidoglu, Cem; Leonard, John; Unutmaz, Derya
ISI:000389941702187
ISSN: 1538-7445
CID: 2411312

CNS neutrophilic vasculitis in neuro-Sweet disease

Charlson, Robert; Kister, Ilya; Kaminetzky, David; Shvartsbeyn, Marianna; Meehan, Shane A; Mikolaenko, Irina
PMID: 26231258
ISSN: 1526-632x
CID: 1698722

Circulating Memory T Cells Isolated from Hodgkin Lymphoma Patients Display Evidence of Exhaustion and Chronic Activation [Meeting Abstract]

Diefenbach, Catherine S; Raphael, Bruce G; Hymes, Kenneth B; Moskovits, Tibor; Kaminetzky, David; Martin, Peter; Ruan, Jia; Lauro, Stephanie; Banks, Danielle; Brown, Krysten; Bonakdar, Maryam; Abidoglu, Cem; Kozhaya, Lina; Leonard, John P; Unutmaz, Derya
ISI:000349233804059
ISSN: 1528-0020
CID: 1497562

Comparison of Graft Content and Efficiency of T Cell Depletion in Bone Marrow and Peripheral Blood Stem Cells Grafts After Manipulation by Three Negative or Positive CD34+Selection Strategies [Meeting Abstract]

Collins, Nancy H.; Kaminetzky, David; Koehne, Guenther; Maloy, Molly; Chen, Xiashe; Smith, Katherine; Bleau, Sharon; Tonon, Jo-ann; Meagher, Richard.; Papadopoulos, Esperanza; Young, James; Giralt, Sergio A.; O'Reilly, Richard; Jakubowski, Ann A.
ISI:000314441900408
ISSN: 1083-8791
CID: 227242

The Chemotherapy Regimen IVAC Is Highly Active for Multiply Relapsed and Refractory Hodgkin Lymphoma [Meeting Abstract]

Diefenbach, Catherine S.; Kaminetzky, David; Andersen, Shannon; Chin, Jane; MacGregor-Cortelli, Barbara; Zain, Jasmine M.
ISI:000314049604378
ISSN: 0006-4971
CID: 227432